Graybug Vision, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Request demo

Graybug Vision, Inc. - overview

About

Founded in 2011 and based in California, US, Graybug Vision, Inc. is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of ocular diseases such as glaucoma and corneal graft rejection. The company offers GB-102, a clinical-stage depot formulation for the treatment of wet age0-related degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).

Current Investors

OrbiMed Advisors, Hatteras Venture Partners, Clarus Ventures

Request a demo

Primary Industry

Pharmaceuticals

Sub Industries

Optometrists & Opticians Products and Services, Pharmaceutical Research & Development

Website

www.graybug.vision

Company Stage

Series C/Round 3

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.

Request demo